Quick Answer
CNS Pharmaceuticals, Inc. reported Stockholders Equity of $4.52 million for the year ending 2025.
- CNS Pharmaceuticals, Inc. showed a decrease of -26.8% in Stockholders Equity from 2024 to 2025.
- This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $35.0 thousand | Q2 2018: -$197.8 thousand | Q3 2018: -$347.0 thousand | Q1 2019: -$716.8 thousand | Q2 2019: $377.7 thousand | Q3 2019: $216.00 | Q1 2020: $5.88 million | Q2 2020: $3.72 million | Q3 2020: $2.47 million | Q1 2021: $11.24 million | Q2 2021: $12.41 million | Q3 2021: $9.10 million | Q1 2022: $13.98 million | Q2 2022: $10.70 million | Q3 2022: $7.57 million | Q1 2023: $3.49 million | Q2 2023: $2.45 million | Q3 2023: -$1.74 million | Q1 2024: -$4.43 million | Q2 2024: -$4.29 million | Q3 2024: $3.35 million | Q1 2025: $10.97 million | Q2 2025: $13.12 million | Q3 2025: $9.91 million.
- Over the full 9 years of available data (2017 to 2025), CNS Pharmaceuticals, Inc.'s Stockholders Equity has grown by 7,826.6%.
- Historical annual values: Fiscal year 2025: $4.52 million | Fiscal year 2024: $6.18 million | Fiscal year 2023: -$4.43 million | Fiscal year 2022: $8.13 million | Fiscal year 2021: $6.16 million | Fiscal year 2020: $13.95 million | Fiscal year 2019: $7.60 million | Fiscal year 2018: -$549.3 thousand | Fiscal year 2017: -$58.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: